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Brain iron accumulation affects myelin-related molecular
systems implicated in a rare neurogenetic disease family
with neuropsychiatric features
M Heidari1,14, DM Johnstone2,14, B Bassett1, RM Graham3, ACG Chua4,5, MJ House6, JF Collingwood7, C Bettencourt8,9, H Houlden8,
M Ryten8,10 for the UK Brain Expression Consortium (UKBEC), JK Olynyk3,11,12,13, D Trinder4,5 and EA Milward1
The ‘neurodegeneration with brain iron accumulation’ (NBIA) disease family entails movement or cognitive impairment, often with
psychiatric features. To understand how iron loading affects the brain, we studied mice with disruption of two iron regulatory
genes, hemochromatosis (Hfe) and transferrin receptor 2 (Tfr2). Inductively coupled plasma atomic emission spectroscopy
demonstrated increased iron in the Hfe− /−× Tfr2mut brain (P= 0.002, n ≥ 5/group), primarily localized by Perls’ staining to
myelinated structures. Western immunoblotting showed increases of the iron storage protein ferritin light polypeptide and
microarray and real-time reverse transcription-PCR revealed decreased transcript levels (Po0.04, n ≥ 5/group) for five other NBIA
genes, phospholipase A2 group VI, fatty acid 2-hydroxylase, ceruloplasmin, chromosome 19 open reading frame 12 and ATPase type
13A2. Apart from the ferroxidase ceruloplasmin, all are involved in myelin homeostasis; 16 other myelin-related genes also showed
reduced expression (Po0.05), although gross myelin structure and integrity appear unaffected (P40.05). Overlap (Po0.0001) of
differentially expressed genes in Hfe− /−× Tfr2mut brain with human gene co-expression networks suggests iron loading influences
expression of NBIA-related and myelin-related genes co-expressed in normal human basal ganglia. There was overlap (Po0.0001)
of genes differentially expressed in Hfe− /−× Tfr2mut brain and post-mortem NBIA basal ganglia. Hfe− /−× Tfr2mut mice were
hyperactive (Po0.0112) without apparent cognitive impairment by IntelliCage testing (P40.05). These results implicate myelin-
related systems involved in NBIA neuropathogenesis in early responses to iron loading. This may contribute to behavioral
symptoms in NBIA and hemochromatosis and is relevant to patients with abnormal iron status and psychiatric disorders involving
myelin abnormalities or resistant to conventional treatments.
Molecular Psychiatry advance online publication, 5 January 2016; doi:10.1038/mp.2015.192
INTRODUCTION
Abnormalities in brain iron may contribute to various psychiatric
disorders, including major depression, bipolar disorder and
autism,1–3 and to diseases such as Alzheimer’s disease, Parkinson’s
disease and Huntington’s disease, that can have psychiatric
features.4,5 Psychiatric symptoms are also a feature of the rare
neurogenetic disease family termed ‘neurodegeneration with
brain iron accumulation’ (NBIA), characterized by iron accumula-
tion in the basal ganglia.6 Patients usually have movement
disorders such as dystonia, spasticity or parkinsonism, often
accompanied by neuropsychological and psychiatric features,
including delusions, hallucinations, personality changes with
emotional lability, depression or violent outbursts, impulsivity,
hyperactivity, poor attention span or cognitive impairment.6–9
Although NBIAs are typically severely debilitating and sometimes
fatal,4,5 the more common iron loading disease hemochromatosis is
generally less severe and specific neuropsychiatric symptoms are
not widely recognized features.4 However, several case reports
document specific psychiatric conditions such as bipolar, major
depressive and psychotic disorders in small numbers of hemochro-
matosis patients, including several instances where patients
resistant to conventional psychiatric treatments experienced partial
or complete recovery following phlebotomy or chelation
treatment.10 Larger studies assessing iron are almost nonexistent,
but one study of psychiatric clinic outpatients estimated a systemic
iron overload prevalence of 1%, associated with an unexpectedly
high rate of diagnoses of bipolar affective disorder (80%) and,
without exception, atypical resistance to psychiatric treatment.2
The mechanisms by which iron perturbation affects the brain
are poorly understood, mainly because of lack of good models.
Past rodent models typically examined short-term iron loading
using injection or iron-supplemented diet,4 whereas human iron
1School of Biomedical Sciences and Pharmacy, The University of Newcastle, Callaghan, NSW, Australia; 2Bosch Institute and Discipline of Physiology, University of Sydney, Sydney,
NSW, Australia; 3School of Biomedical Sciences and Curtin Health Innovation Research Institute - Biosciences, Curtin University of Technology, Bentley, WA, Australia; 4School of
Medicine and Pharmacology, University of Western Australia, Fiona Stanley Hospital, Murdoch, WA, Australia; 5Harry Perkins Institute of Medical Research, Murdoch, WA, Australia;
6School of Physics, University of Western Australia, Crawley, WA, Australia; 7Warwick Engineering in Biomedicine, School of Engineering, University of Warwick, Coventry, UK;
8Department of Molecular Neuroscience, UCL Institute of Neurology, London, UK; 9Department of Clinical and Experimental Epilepsy, UCL Institute of Neurology, London, UK;
10Department of Medical and Molecular Genetics, King’s College London, London, UK; 11Institute for Immunology and Infectious Diseases, Murdoch University, Perth, WA,
Australia; 12Department of Gastroenterology and Hepatology, Fiona Stanley Hospital, The University of Western Australia, Murdoch, WA, Australia and 13Department of
Gastroenterology and Hepatology, Fremantle Hospital, Fremantle, WA, Australia. Correspondence: Dr L Milward, School of Biomedical Sciences and Pharmacy MSB, University of
Newcastle, Callaghan, NSW 2308, Australia.
E-mail: Liz.Milward@newcastle.edu.au
14These two authors contributed equally to this work.
Received 13 June 2015; revised 1 October 2015; accepted 26 October 2015
Molecular Psychiatry (2016), 1–9
© 2016 Macmillan Publishers Limited All rights reserved 1359-4184/16
www.nature.com/mp
loading disorders usually involve slow iron accumulation
over extended periods, with damage often only apparent later in
life.4
Genetically modified mice provide better models of
chronic, progressive human iron loading. We and others have
investigated the brain iron phenotype of mice with disruption
of the Hfe gene (Hfe− /−) or the transferrin receptor 2 gene
(Tfr2mut), the iron regulatory genes causatively associated with
hemochromatosis.11–13 However, although these models display
chronic systemic iron loading, brain iron content remained
unchanged at all ages investigated,11,12 as also reported for a
related Hfe H67D mutation ‘knock-in’ mouse model.14
A new genetic mutant mouse model with simultaneous
disruption of the Hfe and the Tfr2 genes (Hfe− /−× Tfr2mut) on an
AKR background shows signs of early liver damage in the form of
fibrosis, equivalent to mild clinical hemochromatosis.15 Hemo-
chromatosis in patients with dual mutations in these two genes is
typically of earlier onset but otherwise often clinically indis-
tinguishable from hemochromatosis caused by either mutation
alone.16–19
In this study, Hfe− /−× Tfr2mut mice fed a short-term high-iron
diet, to maximize iron phenotype, showed increased brain iron
loading, the first such demonstration in a hemochromatosis
model, accompanied by hyperactivity and other behavioral
changes. (As previously reported, AKR wild-type control mice on
this diet do not show brain iron increases.20) Iron accumulated
preferentially in myelinated tracts throughout the brain and in a
subset of myelin-associated oligodendroglial cells, with few if any
neurons, astrocytes or microglia showing discernible iron staining.
This was accompanied by numerous molecular changes, including
alteration of six NBIA-associated transcript or protein species. As
far as we are aware, this is the first demonstration that brain iron
loading influences the expression of a suite of genes causatively
linked to NBIA.
We found that most of the NBIA-linked genes with altered
expression in response to brain iron loading are directly or
indirectly related to myelin and that several other myelin-related
genes also show expression changes in the mouse model. There
was significant correspondence between genes that are differen-
tially expressed in mouse brain in response to increased iron
loading and a gene co-expression set from human brain basal
ganglia that is enriched for both NBIA-related genes and genes
related to myelin or oligodendrocytes. There was also overlap with
genes identified as differentially expressed in basal ganglia from
NBIA cases that were significantly enriched for various myelin-
related ontologies. As myelin changes are hypothesized to
contribute to many psychiatric disorders, including schizophrenia,
bipolar disorder and depression,21,22 these findings raise the
possibility of a relationship between iron, myelin and the
psychiatric symptoms observed in some NBIA cases.
MATERIALS AND METHODS
Mice and tissue collection
Cross-breeding of homozygous Hfe− /− mice and Tfr2mut mice on an AKR
genetic background23,24 generated mice homozygous for both
mutations.15 The AKR background manifested stronger iron loading than
other genetic backgrounds to which it was compared.25,26 Unless
otherwise stated, all experiments were performed on male mice. Mice
were maintained ad libitum on a standard diet containing ∼ 0.02% iron. To
maximize iron status, Hfe− /−xTfr2mut mice were switched to an iron-
supplemented diet containing 2% carbonyl iron (Sigma Aldrich, St Louis,
MO, USA) for 3 weeks before killing. At 13 weeks of age, mice were killed
under anesthesia (50mg kg− 1 ketamine, 10 mg kg− 1 xylazine; Troy
Laboratories, Pty Ltd, Smithfield, NSW, Australia). Mice were perfused
transcardially with isotonic saline, brains excised, snap-frozen in liquid
nitrogen and stored at − 80 °C. All protocols were approved by the Animal
Ethics Committees of the Universities of Western Australia and Sydney.
Measurement of iron and ferritin
Homogenized brain tissue (150mg) from wild-type and Hfe− /−× Tfr2mut
mice (n ≥ 5/group) was digested with concentrated nitric acid (69%, 10ml,
60 °C). After solubilization, samples were heated to 95 °C until volume was
reduced to ~ 1ml. Samples were diluted to ~ 8ml in 1% nitric acid and
iron, cadmium, copper, manganese, lead, selenium and zinc measured
by inductively coupled plasma atomic emission spectroscopy at the Marine
and Freshwater Research Laboratory, Murdoch University, Perth, Australia.
Ferritin and β-actin protein levels were assessed by western immuno-
blotting as previously described12 (see Supplementary Table 1 for antibody
details).
RNA microarray preparation and analysis
Total RNA was isolated from Hfe− /−× Tfr2mut and wild-type mice (n ≥ 4/
group) using TRI reagent (Ambion) and then purified and concentrated
using the RNeasy MinElute Kit (QIAGEN, Hilden, Germany) and quantified
by spectrophotometry. RNA samples were biotin labeled and amplified
using the TotalPrep RNA Amplification Kit (Ambion, Austin, TX, USA). cRNA
was hybridized onto Sentrix MouseRef-8 v2 Expression BeadChips
(Illumina, San Diego, CA, USA) and scanned using the Illumina BeadArray
Reader and BeadScan software (V2.2.7). After data preprocessing with the
GenomeStudio Gene Expression Module (Illumina, v2010.3) and back-
ground subtraction and normalization (Average or Cubic Spline), data were
filtered to remove genes not expressed above background levels using a
detection P-value filter of 0.01, as recommended by Illumina. Cluster
analysis confirmed similarity of global gene expression profiles between
the individual samples in each group and hence all samples were included
in the final analyses. Differential expression analysis was then performed
using GenomeStudio or GeneSpring GX 7.3 (Agilent Technologies, Santa
Clara, CA, USA). No multitest correction was applied for discovery-driven
experiments.27 All analyses were performed on both the union and the
intersection gene lists generated from the four data sets (that is, Average-
or Cubic Spline-normalized probes analyzed by GenomeStudio and
Average- or Cubic Spline-normalized probes analyzed by GeneSpring).28
Unless otherwise stated, all reported outcomes were observed for both
gene lists. To validate microarray data, real-time reverse transcription-PCR
was performed as previously described.11 For primer sequences see
Supplementary Table 2. Transcript levels of genes of interest were
normalized to the geometric mean expression of Actb, Gapdh, Hprt and
Rpl13a. Enriched pathways and ontologies were identified by DAVID
(http://david.abcc.ncifcrf.gov/home.jsp), KEGG (http://www.genome.jp/
kegg/) and GATHER (http://gather.genome.duke.edu/).
Comparison with human normal and NBIA basal ganglia
transcriptomes
Differentially expressed genes in the Hfe− /−× Tfr2mut brain were compared
with a set of genes showing expression correlations in human basal
ganglia and enriched for both NBIA-related genes and genes related to
myelin and oligodendrocytes. This gene set was identified by unsupervised
weighted gene co-expression network analysis of whole-transcriptome
profiles from 10 brain regions in neuropathologically normal adult brain
(n= 101).29
In a separate analysis, differential gene expression was assessed in post-
mortem basal ganglia of two clinicopathologically confirmed NBIA cases of
unknown genetic subtype (male 66 years and female 81 years) from the
Canadian Brain Tissue Bank, University of Toronto, compared with two age-
and gender-matched adults with no diagnosed neurological conditions
from the Newcastle Brain Tissue Resource, University of Newcastle, UK.
Tissue was obtained with fully informed consent and the study approved
by the Human Research Ethics Committee of the University of Newcastle,
Australia (H-2010-1219). Total RNA was isolated and prepared for
microarray as previously described.11,12 Microarrays were performed using
HumanHT-12 v4 Expression BeadChips (Illumina). Following Cubic Spline
normalization in GenomeStudio (Illumina, v2010.3), genes were considered
differentially expressed if the fold change of the mean NBIA signal relative
to mean control signal was at least 1.5. Pathways were analyzed by DAVID
and the gene list also compared with the NBIA- and myelin-related gene
set identified from the human basal ganglia co-expressed gene list
described above,29 with significant overlap determined by χ2 testing
(Po0.05). The array data from the Hfe− /−× Tfr2mut mice (GSE70431), NBIA
basal ganglia (GSE70430) and normal brain (GSE46706) have been
deposited for public access at Gene Expression Omnibus.
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Histology and immunohistochemistry
Mouse brains (n ≥ 4/group) were perfusion fixed (4% paraformaldehyde)
and cryosectioned (20 μm). Iron was detected by 3,3′-diaminobenzidine-
enhanced Perls’ stain.30 Antibodies for immunohistochemical analysis of
myelin and cell identification are detailed in Supplementary Table 1.
Myelin quantification (n ≥ 4 mice/group) was performed between
anterioposterior Bregma coordinates of − 1.46 to − 2.18. Triplicate sections
were stained with Luxol Fast Blue (IHC World, Woodstock, MD, USA) and
digitized with the Aperio Digitial Pathology System (Leica Biosystems,
Wetzlar, Hesse, Germany). Corpus callosum width and area were measured
as described elsewhere31,32 and Luxol Fast Blue staining density quantified
with the Aperio ImageScope Positive Pixel Count tool (Version 12.1.0.5029),
as illustrated in Figure 1e (for specific algorithm parameters see
Supplementary Table 3).
Transmission electron microscopy
To determine whether changes in myelin ultrastructure accumulated later
in life, ultrathin sections (70–90 nm) of corpus callosum around the midline
(−1.46 to − 2.18 Bregma) were prepared from 2 male and 2 female mice
per group at 9–11 months of age using published methods.33 Ten
randomly selected fields per animal were imaged on a JEOL JEM-1200EXII
(Tokyo, Japan) transmission electron microscope. Number of myelinated
axons per 100 μm2, cross-sectional area, thickness of myelinated axons
(n4100) and ‘g-ratio’ of axon thickness relative to myelin sheath thickness
were obtained using ImageJ (National Institutes of Health, Bethesda,
MA, USA).
Behavioral study
Cognitive function was tested with the IntelliCage system (NewBehavior AG,
Zürich, Switzerland) using a published place learning protocol comprising
3 days of habituation and 3 days of nose-poke adaptation, followed by
5 days of place learning and 5 days of reversal of place learning.34 Groups
of 9-month-old wild-type and Hfe− /−×Tfr2mut mice (n= 6/group, equal
numbers of male and female) were housed in separate IntelliCages. Two
female wild-type mice were excluded during the experiment because of
inadequate drinking activity, in accordance with IntelliCage criteria.34
RESULTS
Brain iron status
As shown in Figure 1a, total iron levels, measured by inductively
coupled plasma atomic emission spectroscopy, were higher in
whole-brain homogenate from Hfe− /−× Tfr2mut mice than wild-
type mice (fold change 1.42, P= 0.002, n ≥ 5/group). There were
no significant differences (P40.05) for copper, zinc and manga-
nese, whereas cadmium, lead and selenium were below detection
limits.
Western immunoblotting of whole-brain homogenate and
quantification by densitometry revealed 2.3-fold increased levels
of ferritin protein (P= 0.0005, n ≥ 5/group) in the Hfe− /−× Tfr2mut
mouse brain relative to wild-type (Figures 1b and c and Table 1).
Microarray analysis and NBIA-related gene expression
In total, 12 318 probes passed the detection P-value cutoff of 0.01
following normalization and were retained in the analysis. The
union list generated by normalization and differential expression
analysis contained 2615 probes, whereas the intersection set
contained 761 probes. Most gene expression changes (95.7%)
were below twofold in magnitude.
Functional classification using DAVID and GATHER identified 11
significantly overrepresented pathways (Po0.05), including path-
ways related to oxidative phosphorylation and neurodegenerative
diseases, notably Parkinson’s disease, Alzheimer’s disease, Hunting-
ton’s disease and amyotrophic lateral sclerosis (Supplementary
Figure 1). Another overrepresented pathway was mitogen-activated
protein kinase signaling. Intriguingly, the gene showing the greatest
expression change in this pathway was phospholipase A2, group VI
(Pla2g6; fold change − 1.60, P=0.010). The NBIA PLA2G6-associated
neurodegeneration is caused by mutations in this gene.35
Of the 10 genes with mutations causatively linked to NBIA, 5
showed reduced transcript levels in Hfe− /−× Tfr2mut brain relative
to wild-type (Table 1: Pla2g6; fatty acid 2-hydroxylase (Fa2h);
ceruloplasmin (Cp); chromosome 19 open reading frame 12
(C19orf12); ATPase type 13A2 (Atp13a2)). The array did not include
effective probes for ferritin light polypeptide (Ftl), another NBIA-
linked gene, but no significant difference in Ftl transcript levels
was observed by real-time reverse transcription-PCR, providing
evidence that the increased levels in ferritin protein noted above
reflect post-transcriptional regulation, as typically occurs in many
iron loading scenarios.36 The χ2 testing revealed that significantly
more NBIA-linked genes showed altered expression than would be
predicted by chance alone (P= 0.009). Transcripts for four other
NBIA-related genes (Table 1) did not differ significantly. All results
were confirmed by real-time reverse transcription-PCR (Figure 1d).
Expression changes of genes related to myelin
Except for Cp, which encodes a ferroxidase,37 none of the NBIA
genes with altered expression have well-established roles in iron
homeostasis. However, one common feature is that all are
associated with NBIA phenotypes showing pathological features
of demyelination.8,38–41 The proteins encoded by these genes are
still not well characterized but there is mounting evidence for
myelin-related functions41–43 (Supplementary Table 4). Another 16
transcripts relating to myelin also showed decreased levels in
Hfe− /−× Tfr2mut brain (all Po0.05), including transcripts for the
iron transporter transferrin that is expressed in oligodendrocytes
and is essential for myelination.44 No myelin-related transcripts
showed significant increases (Supplementary Table 5).
Comparison of gene expression changes in the Hfe− /−× Tfr2mut
brain with a human basal ganglia gene expression network
relevant to NBIA and myelin
We compared gene expression changes in Hfe− /−× Tfr2mut brain
with a network of genes showing expression correlations in
normal human basal ganglia that is enriched for both NBIA-related
genes and genes related to myelin and oligodendrocytes. There
was significant overlap between this human network and genes
differentially expressed in the Hfe− /−× Tfr2mut mouse brain
(Po0.0001).
Comparisons with gene expression in the basal ganglia of NBIA
cases
The rarity of NBIA makes obtaining post-mortem brain samples
difficult but we performed restricted array analysis of post-mortem
basal ganglia from two clinicopathologically confirmed NBIA
patients and matched controls. The χ2 analysis showed significant
overlap of putative differentially expressed genes from NBIA
brains and Hfe− /−× Tfr2mut mice brains (Po0.0001).
There were no consistent changes in levels of prominent iron-
related transcripts in these cases, with levels of most iron-related
transcripts appearing unaltered, including ferritin and ceruloplas-
min transcripts, although transcripts for the ferroxidase hephaes-
tin were identified as being downregulated in tissue from one
NBIA patient but not the other. However, numerous myelin-
related transcripts were identified as differentially expressed in
both NBIA brains (Supplementary Table 6).
Pathway and ontology analysis, using DAVID, of genes
identified in NBIA brains showed significant enrichment of several
myelin-related ontologies, notably ‘myelin sheath’, ‘adherens
junction’, ‘focal adhesion’ and ‘fatty acid metabolic processes’
(all Po0.05). Other pathways that were enriched in the set of
common genes identified as differentially expressed in both
Hfe− /−× Tfr2mut mouse and NBIA brains again included pathways
relating to neurodegenerative diseases (specifically Alzheimer’s
disease, Parkinson’s disease and Huntington’s disease), oxidative
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phosphorylation and the mitogen-activated protein kinase
pathway (Supplementary Figure 1).
Iron accumulates in myelin tracts and myelin-associated cells
Iron labeling with 3,3′-diaminobenzidine-enhanced Perls’ stain
and Luxol Fast Blue myelin staining showed that iron accumulates
preferentially in myelinated tracts throughout the brain
(Figures 2a–c) and in a subset of myelin-associated oligoden-
droglial lineage cells expressing the oligodendrocyte transcription
factor Olig2 (Figure 2d). Few, if any, neurons, astrocytes or
microglia showed high levels of iron staining (Figure 2d).
Myelinated structures and iron-loaded oligodendroglial cells
generally appeared morphologically normal (Figures 1e–h and
2). No differences were observed in measures of total myelin by
Luxol Fast Blue staining density, corpus callosum width and area
or measures of myelin ultrastructure from electron micrographs,
including axon cross-sectional area, g-ratio and number of
myelinated axons (all P40.05).
Cognitive and behavioral testing
As shown in Figures 1i and j, Hfe− /−× Tfr2mut mice showed
hyperactivity in the habituation and nose-poke adaptation phases
of IntelliCage testing, with increased numbers of exploratory visits
to cage monitoring areas (two-way analysis of variance Po0.0112
and Po0.0004 respectively), in conjunction with significantly
increased visit durations in these phases (two-way analysis of
variance Po0.0007 and Po0.0001 respectively). There was no
effect of genotype on cognitive function assessed by performance
Figure 1. (a) Whole-brain iron levels by inductively coupled plasma atomic emission spectroscopy (ICP-AES). Mean± s.e.m., Student’s t-test
*P=0.002, n ≥ 5/group. (b and c) Immunoblot analysis of ferritin relative to β-actin. Mean± s.e.m., Student’s t-test *P=0.0005, n ≥5 per group. (d)
Real-time reverse transcription-PCR (RT-PCR) validation of changes in transcript levels for selected neurodegeneration with brain iron
accumulation (NBIA) genes. Mean± s.e.m., Student’s t-test *Po0.04, n= 7/group. (e) Luxol Fast Blue staining (left panels) was analyzed by the
Positive Pixel Count algorithm (right panels) that grades areas as high (red), moderate (orange) or weak (yellow) positive or negative (blue)
staining. (f and g) Average density (total intensity of all positive pixels divided by total number of positively stained pixels) and positivity (number
of positive pixels divided by the total pixels; measures proportion of brain area staining positive) of Luxol Fast Blue staining for myelin were
unchanged. Mean± s.e.m., Mann–Whitney test P40.05, n≥4/group. (h) Electron micrographs of myelinated axons (top) and glial cell organelles
(bottom) in the corpus callosum; oligodendrocyte mitochondria (red arrows) and Golgi apparatus (yellow stars). (i and j) Activity measures
(number of visits and duration of visits per test group per day) in the habituation (Habit.) and nose-poke adaptation (NPA) phases of IntelliCage
testing. Mean± s.e.m., two-way ANOVA (i) *Po0.0112 (Habit.) and **Po0.0004 (NPA); (j) *Po0.0007 (Habit.) and **Po0.0001 (NPA), n ≥6/group.
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in the place learning task or reversal of place learning task
(two-way analysis of variance P40.05).
DISCUSSION
This study demonstrates that increased iron levels in the
Hfe− /−× Tfr2mut mouse brain are accompanied by decreased
expression of a suite of NBIA-linked genes in conjunction with
changes in mouse behavioral activity patterns. Iron was localized
primarily to myelinated structures and was also present in a subset
of myelin-associated oligodendroglial cells. Aside from Ftl, no
NBIA-related transcripts show altered expression in either the
Hfe− /− or Tfr2mut single mutant models that do not have increased
brain iron.11,12 Of the six NBIA-linked genes (Pla2g6, Fa2h, Cp,
C19orf12, Atp13a2 and Ftl) with altered transcript or protein
expression in the Hfe− /−× Tfr2mut brain, only Cp and Ftl are directly
implicated in iron homeostasis, encoding a ferroxidase important
in iron export37 and an iron storage protein, respectively.45
However, the remaining genes have putative functions relating to
myelin, an important site of brain iron storage.41–43,46–48 In
addition, we observed expression changes in other myelin-related
genes in the iron-loaded mouse brain and enrichment of
myelin-related ontologies in human NBIA brain, further supporting
connections between iron, myelin and NBIA.
Our study provides evidence for ceruloplasmin gene regulation
in response to iron levels, consistent with an earlier study in rats.49
This may help protect against excessive brain iron accumulation as
moderate reductions in Cp transcripts could potentially reduce
export of iron from cerebrovascular endothelial cells into the
brain.50,51 Ceruloplasmin deficiency is not usually associated with
myelin changes but FTL-linked NBIA (neuroferritinopathy) often
involves extensive myelin loss.47 Ferritin expression is typically
regulated post-transcriptionally through the iron-responsive ele-
ment/iron-regulatory protein system without requiring concomi-
tant changes in transcript levels.36 The increased Hfe− /−× Tfr2mut
brain ferritin protein levels we observed are consistent with an
iron-responsive element/iron-regulatory protein system feedback
mechanism triggered by increased brain iron levels that may help
protect against damage by increasing intracellular iron storage
capacity. The other NBIA genes showing expression changes do
not have recognized iron-regulatory roles but may indirectly
influence iron homeostasis, as all have connections to myelin, the
main brain iron reservoir.52 All are associated with phenotypes
that can involve myelin pathology8,38–41 and several encode
proteins with functions relating to myelin.41–43,46 Delayed
myelination or disruption of myelin integrity occur in patients
with PLA2G6-linked and FA2H-linked NBIA.38–40,53,54 Of the known
NBIA genes, these have the strongest links to myelin and also
showed the greatest changes in iron-loaded mouse brains.
Products of pla2g6 activity are required for myelin
homeostasis55–57 and FA2H is crucial for biosynthesis of myelin
lipid components.58,59 Patients with C19orf12 and ATP13A2
mutations show myelin reduction8,41,60 and we observed
decreased expression of these genes in iron-loaded mouse brains.
C19orf12 may be involved in fatty acid biogenesis41 and atp13a2
is a putative phospholipid flippase that translocates phospholipids
across membranes7,61 and may protect against iron cytotoxicity
through effects on membrane permeability.62
The four NBIA-related genes that did not show expression
changes are less strongly linked to myelin, although rare cases of
WDR45-linked NBIA63,64 and DCAF17-linked NBIA show subtle
white matter changes.65,66 The PANK2 protein, involved in
coenzyme A metabolism,67 does not appear to be associated
with clear myelin pathology.68,69 We found no reports of myelin
pathology in NBIAs involving COASY but there is little published
neuropathology for these patients. The extent to which iron
abnormalities cause myelin perturbations may depend partly on
location. For example, in patients with PANK2 mutations, iron
accumulation appears mainly restricted to neurons and astrocytes,
with sparing of oligodendrocytes,68 perhaps explaining why
myelin pathology is not typically observed in these patients.
Table 1. NBIA-related genes investigated in the Hfe− /−× Tfr2mut mouse brain










Phospholipase A2, group VI
(Pla2g6)
Fatty acid release from
phospholipids
↓1.60 (0.010) PLAN Yes MRI MRI
Fatty acid 2-hydroxylase (Fa2h) 2-Hydroxy sphingolipid
synthesis
↓1.41 (0.002) FAHN Yes MRI MRI,
animal
study
Ceruloplasmin (Cp) Oxidation of
Fe(II) to Fe(III)
↓1.35 (0.013) Aceruloplasminemia Yes MRI, post-mortem,
animal study
No
Chromosome 19 open reading
frame 12 (C19orf12)
Fatty acid biogenesis ↓1.28 (0.023) MPAN Yes MRI, post-mortem MRI






Ferritin, light polypeptide (Ftl) Iron storage ↑2.3 (0.0005)a Ferritinopathy Yes MRI, animal model Post-
mortem
Pantothenate kinase 2 (Pank2) Biosynthesis of CoA NS PKAN Yes MRI, post-mortem No
CoA synthase (Coasy) Biosynthesis of CoA
from pantothenic acid
NS CoPAN Yes MRI NA
WD repeat domain 45 (Wdr45) Autophagy NS BPAN Yes MRI MRI
DDB1 and CUL4 associated
factor 17 (Dcaf17)
Ubiquitin ligase NS Woodhouse–Sakati
syndrome
Yes MRI MRI
Abbreviations: BPAN, β-propeller protein-associated neurodegeneration; FAHN, fatty acid hydroxylase-associated neurodegeneration; MPAN, mitochondrial
membrane protein-associated neurodegeneration; MRI, magnetic resonance imaging; NA, no reported data available; NBIA, neurodegeneration with brain
iron accumulation; NS, nonsignificant (P40.05); PKAN, pantothenate kinase-associated neurodegeneration; PLAN, PLA2G6-associated neurodegeneration. Data
are presented as fold change and associated P-value is in brackets. aBy western immunoblotting.
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Myelin-related effects in the Hfe− /−× Tfr2mut brain were not
limited to NBIA-associated genes but also included decreased
levels of 16 other transcripts with roles in myelin formation,
integrity and regulation (Supplementary Table 5). These included
transcripts for transferrin that is important in both brain iron
transport and myelination.44,70 Although decreases in expression
of myelin structural genes such as Mobp, which stabilizes myelin,
may affect myelin integrity, some of the other downregulated
myelin-related genes are negative regulators of oligodendrocyte
survival, maturation or myelin production (see Supplementary
Table 5 for Rtn4, Tnfrsf21 and Lingo1), suggesting myelin repair or
fresh synthesis may compensate for myelin abnormalities and
help preserve myelin integrity.
Substantial myelin changes are not expected in our mouse
model, as it represents early hemochromatosis that does not have
brain abnormalities comparable to NBIA, where severe problems
often occur in childhood. Even so, the extensive transcriptomic
alterations provide evidence that the normal equilibrium of
myelin-related systems is still perturbed in these mice, and
this may increase vulnerability to stressors despite the absence of
gross myelin changes. We do not yet know whether iron
accumulates in myelin itself or, perhaps more likely, in the
periaxonal space (or both) in this model, but in all these scenarios
axonal health as well as myelin health could eventually be
affected. This merits detailed future studies.
Further evidence that brain iron perturbation can affect
myelin comes from a mouse model deficient in iron-responsive
element-binding protein 2 (also called iron-regulatory protein 2).71
This model shows movement impairment and myelin-related
changes accompanying abnormal brain iron deposition.71 How-
ever, NBIA transcript expression was not investigated in this study
and, as far as we know, IRP2 mutations have not been associated
with human disease.
The similarities between the mouse data and human brain gene
co-expression networks suggest increased iron loading selectively
influences expression of a suite of NBIA-related and myelin-related
genes that are co-expressed in normal human basal ganglia. The
overlap between the mouse and NBIA basal ganglia data also
suggests analogies between molecular mechanisms affected by
brain iron loading in mice and pathogenic mechanisms in NBIA
patients and provides evidence for involvement of systems
relating to myelin and oligodendrocytes. Excessive iron loading
in or near myelinated tracts might act on oligodendroglia or
myelin to cause pathogenic or compensatory changes in
transcription of various genes, including some NBIA-related genes.
The mutant mice showed hyperactivity and other behavioral
changes and are considered unusually aggressive by animal
technicians, often requiring housing in separate cages to prevent
fighting (DM Johnstone, unpublished observation). More studies
are planned, including tests of basal ganglia function, as iron
preferentially loads in basal ganglia myelinated tracts, and tests
of aggression and mouse behavioral analogs of depression. In
addition, as far as we are aware, psychiatric abnormalities have yet
to be reported in the NBIA gene mouse models themselves, and
hence additional stressors may be required to elicit abnormal
psychiatric responses in relevant mouse models.
As discussed above, changes in our model are mild relative to
NBIA. The mice do not show functional changes typically associated
with neurodegenerative disease, with no clear cognitive or move-
ment impairment at ages up to 9 months. However, we postulate
that in NBIA patients with mutations in genes important in myelin
or pathological peri-myelin iron accumulation, myelin damage may
result. This may lead to release of iron from myelin stores, further
raising iron levels in a positive feedback amplification cascade.
Numerous studies report perturbations of myelin and myelin-
related systems in psychiatric disorders, with altered myelination
during childhood and adolescence implicated in schizophrenia,
autism and other conditions.21,22 Myelin alteration can affect
synapse formation and plasticity, conduction velocity and
synchronic impulse trafficking between brain regions.72 This can
affect normal mental performance73 and may contribute to
psychiatric symptoms in disorders involving myelin abnormalities,
including some NBIA subtypes.
No studies appear to have examined relationships between
psychiatric symptoms and interdependent abnormalities in iron and
myelin, or the molecular systems involved, although a few studies
hint at possible links. For example, the shift from presymptomatic to
clinical Huntington’s disease, including the development of
psychiatric symptoms, is distinguished by increased white matter
iron with demyelination and axonal degeneration.74
In summary, our findings may provide insights into mechanisms
contributing to behavioral symptoms in patients with NBIA or
conditions such as hemochromatosis and transfusion-induced iron
overload. The findings also have potential relevance to patients
with myelin disorders such as multiple sclerosis as well as to
patients with psychiatric disorders, particularly with suspected
myelin abnormalities or resistant to conventional treatments. The
small existing literature suggests neuropsychiatric patients with
iron overload may respond well to venesection.10 Studies of NBIA
patients with known mutations and of patients with neurobeha-
vioral symptoms and evidence of brain or systemic iron loading
will further illuminate relationships between iron and myelin.
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